Atea 제약, Inc.
US ˙ NasdaqGS ˙ US04683R1068

SecurityAVIR / Atea Pharmaceuticals, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership242,990 shares
Latest Disclosed Value $ 867,474
Barclays Plc reports 0.63% increase in ownership of AVIR / Atea Pharmaceuticals, Inc.

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 242,990 shares of Atea Pharmaceuticals, Inc. (US:AVIR) valued at $867,474 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 241,464 shares of Atea Pharmaceuticals, Inc.. This represents a change in shares of 0.63% during the quarter. The current value of the position is $1,032,708 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F ATEA PHARMACEUTICALS COM 04683R106 242,990 1,526 0.63 867 23.86 0.0002
2026-03-31 2025-09-30 13F/A-3 ATEA PHARMACEUTICALS COM 04683R106 241,464 -20,310 -7.76 700 -25.69 0.0002
2026-03-19 2025-09-30 13F/A-2 ATEA PHARMACEUTICALS COM 04683R106 177,077 -84,697 593 0.0002
2025-11-12 2025-09-30 13F ATEA PHARMACEUTICALS COM 04683R106 241,464 -20,310 700 0.0002
2026-02-27 2025-06-30 13F/A-2 ATEA PHARMACEUTICALS COM 04683R106 261,774 90,462 52.81 942 83.98 0.0002
2025-08-14 2025-06-30 13F/A-1 ATEA PHARMACEUTICALS COM 04683R106 261,774 90,462 1 0.0002
2025-08-13 2025-06-30 13F ATEA PHARMACEUTICALS COM 04683R106 261,774 90,462 1 0.0001
2026-03-17 2025-03-31 13F/A-1 ATEA PHARMACEUTICALS COM 04683R106 171,312 -28,801 -14.39 512 -23.58 0.0001
2025-05-15 2025-03-31 13F ATEA PHARMACEUTICALS COM 04683R106 171,312 -28,801 1 0.0001
2026-03-19 2024-12-31 13F/A-1 ATEA PHARMACEUTICALS COM 04683R106 200,113 23,036 13.01 670 12.98 0.0002
2025-02-13 2024-12-31 13F ATEA PHARMACEUTICALS COM 04683R106 200,113 23,036 1 0.0002
2026-03-31 2024-09-30 13F/A-2 ATEA PHARMACEUTICALS COM 04683R106 177,077 75,624 74.54 593 77.01 0.0002
2024-11-19 2024-09-30 13F/A-1 ATEA PHARMACEUTICALS COM 04683R106 177,077 75,624 1 0.0002
2024-11-15 2024-09-30 13F ATEA PHARMACEUTICALS COM 04683R106 177,077 75,624 1 0.0000
2026-03-23 2024-06-30 13F/A-1 ATEA PHARMACEUTICALS COM 04683R106 101,453 -44,079 -30.29 336 -42.93 0.0001
2024-08-14 2024-06-30 13F ATEA PHARMACEUTICALS COM 04683R106 101,453 -44,079 0 0.0001
2026-03-24 2024-03-31 13F/A-1 ATEA PHARMACEUTICALS COM 04683R106 145,532 -51,555 -26.16 588 -2.33 0.0002
2024-05-15 2024-03-31 13F ATEA PHARMACEUTICALS COM 04683R106 145,532 -51,555 1 0.0002
2026-03-25 2023-12-31 13F/A-1 ATEA PHARMACEUTICALS COM 04683R106 197,087 171,468 669.30 601 690.79 0.0002
2024-02-15 2023-12-31 13F ATEA PHARMACEUTICALS COM 04683R106 197,087 171,468 1 0.0002
2026-03-26 2023-09-30 13F/A-1 ATEA PHARMACEUTICALS COM 04683R106 25,619 10,348 67.76 77 33.33 0.0000
2023-11-07 2023-09-30 13F ATEA PHARMACEUTICALS COM 04683R106 25,619 10,348 0 0.0000
2026-03-30 2023-06-30 13F/A-2 ATEA PHARMACEUTICALS COM 04683R106 15,271 -23,488 -60.60 57 -55.81 0.0000
2023-09-20 2023-06-30 13F/A-1 ATEA PHARMACEUTICALS COM 04683R106 15,271 -23,488 0 0.0000
2023-08-03 2023-06-30 13F ATEA PHARMACEUTICALS COM 04683R106 15,271 -23,488 0 0.0000
2026-03-30 2023-03-31 13F/A-1 ATEA PHARMACEUTICALS COM 04683R106 38,759 12,677 48.60 130 3.20 0.0001
2023-05-04 2023-03-31 13F ATEA PHARMACEUTICALS COM 04683R106 38,759 12,677 0 0.0001
2026-03-30 2022-12-31 13F/A-1 ATEA PHARMACEUTICALS COM 04683R106 26,082 -10,941 -29.55 125 -40.76 0.0001
2023-02-13 2022-12-31 13F ATEA PHARMACEUTICALS COM 04683R106 26,082 -10,941 0 0.0001
2022-11-03 2022-09-30 13F ATEA PHARMACEUTICALS COM 04683R106 37,023 -9,917 -21.13 211 -36.64 0.0002
2022-08-12 2022-06-30 13F ATEA PHARMACEUTICALS COM 04683R106 46,940 -15,070 -24.30 333 -25.67 0.0002
2022-05-16 2022-03-31 13F ATEA PHARMACEUTICALS COM 04683R106 62,010 62,010 448 0.0004
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.